Pomalidomide-C4-NH2 is primarily utilized in the development of targeted cancer therapies, particularly for the treatment of multiple myeloma. Its structure allows for enhanced binding affinity to specific proteins involved in cancer cell proliferation, making it a valuable component in the design of proteolysis-targeting chimeras (PROTACs). These molecules facilitate the degradation of disease-causing proteins, offering a promising approach to combat drug-resistant cancers. Additionally, it is being explored in research for its potential to modulate the immune system, aiding in the suppression of tumor growth. Its applications extend to the synthesis of novel drug conjugates, improving the efficacy and specificity of therapeutic agents in oncology.